Your browser doesn't support javascript.
loading
High-dose-rate brachytherapy with surface applicator in penile cancer.
Saldi, Simonetta; Zucchetti, Claudio; Fulcheri, Christian Paolo Luca; Saccia, Stefano; Alì, Emanuele; Marani, Simona; Ingrosso, Gianluca; Aristei, Cynthia.
Afiliação
  • Saldi S; Section of Radiation Oncology, Perugia General Hospital, Perugia, Italy. Electronic address: simonetta.saldi@ospedale.perugia.it.
  • Zucchetti C; Medical Physics, Perugia General Hospital, Perugia, Italy.
  • Fulcheri CPL; Medical Physics, Perugia General Hospital, Perugia, Italy.
  • Saccia S; Section of Radiation Oncology, Perugia General Hospital, Perugia, Italy.
  • Alì E; Radiation Oncology, Department of Surgical and Biomedical Science, University of Perugia and Perugia General Hospital, Perugia, Italy.
  • Marani S; Radiation Oncology, Department of Surgical and Biomedical Science, University of Perugia and Perugia General Hospital, Perugia, Italy.
  • Ingrosso G; Radiation Oncology, Department of Surgical and Biomedical Science, University of Perugia and Perugia General Hospital, Perugia, Italy.
  • Aristei C; Radiation Oncology, Department of Surgical and Biomedical Science, University of Perugia and Perugia General Hospital, Perugia, Italy.
Brachytherapy ; 20(4): 835-841, 2021.
Article em En | MEDLINE | ID: mdl-33994341
ABSTRACT

PURPOSE:

An alternative to surgery for penile cancer is radiation therapy which is administered with external beam techniques and/or brachytherapy (BT) either interstitial or using a surface applicator. Here we report our experience in penile cancer patients treated with high-dose-rate (HDR)-BT with the surface technique, analyzing dosimetric parameters and clinical outcomes. METHODS AND MATERIALS Between June 2016 and December 2019, 7 patients with squamous cell carcinoma of the penis received HDR-BT by means of customized applicators that were constructed using a 3D printer or thermoplastic mask. The total dose was 57 Gy in 19 fractions.

RESULTS:

Median clinical target volume percentage receiving 95%, 125%, and 150% of the prescribed dose were 93.1% (range 92.2-98.5), 12% (range 7.4-32.2), and 0.24% (range 0-10.8), respectively. Median urethral volumes receiving 90% and 115% of the prescribed dose were 40.2% (range 21.0-83.8) and 0% (range 0-1), respectively. All patients achieved complete remission. No patient developed G3 or G4 acute or late toxicities. No patient experienced urethral stenosis.

CONCLUSIONS:

Surface HDR-BT in penile cancer is feasible and is associated with a high tolerance profile and good outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Penianas / Estreitamento Uretral / Braquiterapia / Carcinoma de Células Escamosas Limite: Humans / Male Idioma: En Revista: Brachytherapy Assunto da revista: RADIOTERAPIA Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Penianas / Estreitamento Uretral / Braquiterapia / Carcinoma de Células Escamosas Limite: Humans / Male Idioma: En Revista: Brachytherapy Assunto da revista: RADIOTERAPIA Ano de publicação: 2021 Tipo de documento: Article